Discovery of Novel GPR119 Agonists with Improved Kinetic Solubility and Drug-like Properties for Type 2 Diabetes Treatment
GPR119 is a compelling therapeutic target for type 2 diabetes due to its role in promoting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucose-dependent insulin secretion. This study aimed to develop a series of novel GPR119 agonists with exceptional kinetic solubility over a...